Collection: Cell Therapy & Bioprocessing

The product path — cells, media, reagents — never contacts open air; transfers happen through sterile-welded tubing and single-use kits. That cuts contamination risk, eases cleanroom requirements, and is the operating principle behind Cytiva's Sepax and Sefia processing systems.

Sepax C-Pro is the compact workhorse for automated processing steps such as density-based mononuclear cell isolation, washing, and volume reduction. The Sefia platform extends the same closed-processing approach to manufacturing scale, combining steps like harvest, wash, and final formulation in one instrument. Many workflows use both at different stages.

For shear-sensitive suspension cultures up to about 25 L, a rocking platform such as the ReadyToProcess WAVE 25 mixes by wave motion in a single-use bag — gentle gas transfer with no impeller and fast turnaround between batches. Xuri systems apply the same format with software and sensor control tailored to immune-cell expansion.

Microfluidic formulation of lipid nanoparticles — mRNA and other nucleic acid payloads are mixed with lipids through NxGen cartridges to give reproducible particle size, from screening scale on the Ignite up to larger batches on the Blaze. It carries an LNP recipe from the bench toward a manufacturable process.

That is the design intent of this portfolio: single-use flow paths, locked software protocols, and matched scale-up steps let a protocol developed on benchtop systems transfer to clinical manufacturing without changing the core unit operations. Cytiva positions Sefia, Sepax, and Xuri together as its cell therapy manufacturing platform.

Israeli labs and manufacturers source Cytiva's cell therapy and bioprocessing lines through Danyel Biotech, the brand's official distributor in the country — from single-use kits kept in local stock to capital systems quoted with installation and training.